TEVA FDA accepts NDA for ecopipam, targets late Q1 2027
TEVA says the FDA has accepted its NDA for ecopipam and set a targeted action date in late Q1 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.